ARWR Stock: Price, Earnings History and SEC Filings
Arrowhead Pharmaceuticals, Inc. (ARWR) last traded at $59.90, down 0.98% on the latest session and down 8.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.36 against an analyst estimate of $-1.23, a miss of 10.6%.
$59.90 -0.98%
1 month-8.48%
52-week high$95.49
52-week low$37.06
Volume1.12M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ARWR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.36 | $-1.23 | -10.57% |
| Mar 2026 | May 7, 2026 | $-0.93 | $-1.18 | +21.19% |
| Dec 2025 | Feb 5, 2026 | $0.22 | $0.60 | -63.33% |
| Sep 2025 | Nov 25, 2025 | $-0.18 | $0.12 | -250.00% |
ARWR beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ARWR
SEC filing data is not available right now. You can search for ARWR on SEC EDGAR.
ARWR news
- 3 Biotech Stocks With Upside Of Up To 80%Oct 31, 2026 · finance.yahoo.com
- Arrowhead gains UK marketing authorisation for RedemploOct 28, 2026 · pharmaceutical-technology.com
- Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce TriglyceridesOct 27, 2026 · finance.yahoo.com
- Arrowhead Pharmaceuticals And 2 Biotech Stocks To OwnOct 24, 2026 · finance.yahoo.com
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) is a US-listed public company on Nasdaq.